In vitro: SUN11602 prevents glutamate-induced neuronal death in primary cultures of rat cerebrocortical neurons. SUN11602 increases the levels of CALB1 gene expression in cerebrocortical neurons. SUN11602 exerts protective effects on hippocampal neurons through activation of FGFR1 and increases CalB expression. SUN11602 promotes neurite outgrowth of primarily cultured rat hippocampal neurons.
In vivo: In WT mice, SUN11602 increases the levels of newly synthesized Calb in cerebrocortical neurons and suppresses the glutamate-induced rise in intracellular Ca2+. This Ca2+-capturing ability of Calb allows the neurons to survive severe toxic conditions of glutamate. Oral administration of SUN11602 at the midpoint of Aβ1-40 and ibotenate injections attenuate short-term memory impairment in the Y-maze test, as well as spatial learning deficits in the water maze task. In addition, the SUN11602 treatment inhibits the increase of peripheral-type benzodiazepine-binding sites (PTBBS),which are a marker for gliosis.
|Cell lines||hippocampal neurons|
|Preparation method||Cerebrocortical neurons are pretreated with vehicle (Hanks’ Balanced Salt Solution), SUN11602, bFGF, or the other growth factors for 24 h prior to the onset of glutamate toxicity. Subsequently, 10 μL of the MTT solution (5 mg/mL) is added to each well (200 μL of culture medium) of the microplates. Neurons in each well are then dried for 24 h, and 200 μL of DMSO is poured into all of the wells in order to dissolve the reaction products thoroughly for the MTT assay|
|Incubation time||24 h|
|Animal models||F344/DuCrj rats|
|Dosages||0.1, 1, and 10 mg/kg|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||37 mg/mL in DMSO|
Disturbances in the FGFR1-5-HT1A Heteroreceptor Complexes in the Raphe-Hippocampal 5-HT System Develop in a Genetic Rat Model of Depression.
Borroto-Escuela DO, et al. Front Cell Neurosci. 2017 Oct 10;11:309. PMID: 29066953.
SUN11602 has basic fibroblast growth factor-like activity and attenuates neuronal damage and cognitive deficits in a rat model of Alzheimer's disease induced by amyloid β and excitatory amino acids.
Ogino R, et al. Brain Res. 2014 Oct 17;1585:159-66. PMID: 25130662.
|Related VEGFR/PDGFR Products|
BFH772 is a potent and selective VEGFR2 inhibitor with an IC50 value of 3 nM.
Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A.
NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.
|EG00229 Trifluoroacetate salt
EG00229 Trifluoroacetate is the first small molecule inhibitor of the neuropilin-1 and VEGF-A interaction with an IC50 of inhibition of 8 uM (125I-VEGF binding to PAE/NRP1 cells).
Apatinib is a selective VEGFR2 inhibitor with IC50 of 1 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.